Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system

Vasilios Papademetriou, Costas P Tsioufis, Ajay Sinhal, Derek Chew, Ian T Meredith, Yuvaraj Malaiapan, Matthew I Worthley, Stephen Grant Worthley

Research output: Contribution to journalArticleResearchpeer-review

56 Citations (Scopus)


Renal denervation has emerged as a novel approach for the treatment of patients with drug-resistant hypertension. To date, only limited data have been published using multielectrode radiofrequency ablation systems. In this article, we present the 12-month data of EnligHTN I, a first-in-human study using a multielectrode ablation catheter. EnligHTN I enrolled 46 patients (average age, 60+/-10 years; on average 4.7+/-1.0 medications) with drug-resistant hypertension. Eligible patients were on >/=3 antihypertensive medications and had a systolic blood pressure (BP) >/=160 mm Hg (>/=150 mm Hg for diabetics). Bilateral renal artery ablation was performed using a percutaneous femoral approach and standardized techniques. The average baseline office BP was 176/96 mm Hg, average 24-hour ambulatory BP was 150/83 mm Hg, and average home BP was 158/90 mm Hg. The average reductions (mm Hg) at 1, 3, 6, and 12 months were as follows: office: -28/-10, -27/-10, -26/-10, and -27/-11 mm Hg (P
Original languageEnglish
Pages (from-to)565 - 572
Number of pages8
Issue number3
Publication statusPublished - 2014

Cite this